ECE2007 Poster Presentations (1) (659 abstracts)
Changes in serum glucose metabolism and growth hormone, cortisol, prolactin, ghrelin, leptin concentrations in normal weight patients with schizophrenia before treatment with atypical antipsychotics
Mirjana Doknic 1 , Nadja Maric 2 , Sandra Pekic 1 , Aleksandar Damjanovic 2 , Dragana Miljic 1 , Marko Stojanovic 1 , Marina Djurovic 1 , Miroslava Jasovic-Gasic 2 , Carlos Dieguez 3 , Felipe Casanueva 4 & Vera Popovic 1
1Institute for Endocrinology, Diabetes and metabolic Diseases, Belgrade, United States; 2Institute for Psychiatry, Belgrade, United States; 3Departement of Physiology, School of Medicine, and Comlplejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; 4Departement of Medicine, School of Medicine, and Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain.
Schizophrenia is a devastating mental illness associated with obesity and diabetes mellitus rates that far exceed those of the general population.
The aim was to evaluate changes in positive energy balance (serum insulin, leptin and ghrelin) and hormones involved in neuroendocrine regulations (serum cortisol, growth hormone and prolactin) before treatment with atypical antypsyhotics (SGA) in normal weight patients with schizophrenia.
Thirty patients with schizophrenia (13 males, mean age 28.9±1.3 years and BMI, 23.3±0.6 kg/m2) treated with antypsyhotics first generation were investigated in this study. They had neither other diseases. The control group included 27 healthy subjects (9 males, mean age 30.7±1.9 years, BMI od 22.8±0.6 kg/m2). Positive family history for diabetes mellitus was similar between groups.
A oral glucose tolerance test (OGTT) with measuring glycemia, insulin, growth hormone and ghrelin was performed in all patients. Fasting samples for leptin, cortisol and prolactin were taken. Patients had normal fasting glucose levels but significantly higher peak glucose levels during OGTT as well as glucose area under the curve (AUC) than control subjects (746±25 vs 650±26 mmol/L/120 min; P<0.01). Fasting insulin levels, as well as insulin AUC did not differ from control subjects at baseline (P>0.05) but peak insulin values were significantly higher in patients with schizophrenia (95.1±14.8 vs 52.2±6.5 mU/L, P<0.05). Growth hormone (GH) and ghrelin levels during OGTT, and leptin concentrations did not differ between patients and control subjects (P>0.05). Cortisol levels (513.3±29.1 vs 441.9±24.3 nmol/L; P<0.05) were higher in patients. Prolactin levels were higher in patients with schizophrenia than in control subjects (821±135 vs 353±45 mU/L; P< 0.01).
Normal weight patients with schizophrenia have already some abnormalities in glucose metabolism therapy and neuroendocrine responses (cortisol, prolactin) before SGA. Thus, shizophrenia could be per se risk factor for diabetes mellitus.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more